The story of the erectile dysfunction drug presents a intricate picture for investors. While the initial release generated substantial profits, the end of its exclusive rights opened the floodgates to generic alternatives, dramatically reducing market share. This poses a unique challenge for drug manufacturers relying on comparable blockbuster prod

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in sales , its intellectual property lapse created Pharma a deluge of knock-off medications, significantly eroding its position . While some businesses may attempt to capitalize on related treatments